Milman Nils, Bergholt Thomas, Eriksen Lisbeth, Byg Keld-Erik, Graudal Niels, Pedersen Palle, Hertz Jens
Department of Obstetrics, Gentofte Hospital, Copenhagen, Denmark.
Acta Obstet Gynecol Scand. 2005 Mar;84(3):238-47. doi: 10.1111/j.0001-6349.2005.00610.x.
To determine the lowest dose of iron preventative of iron deficiency and iron deficiency anemia in pregnancy.
A randomized, double-blind intention-to-treat study comprising 427 healthy pregnant women allocated into four groups taking ferrous iron (as fumarate) in doses of 20 mg (n = 105), 40 mg (n = 108), 60 mg (n = 106), and 80 mg (n = 108) from 18 weeks of gestation. Iron status markers [hemoglobin (Hb), serum ferritin, and serum soluble transferrin receptor (sTfR)] were measured at 18 weeks (inclusion), 32 weeks, and 39 weeks of gestation and 8 weeks postpartum. Side effects of iron supplements were recorded. Iron deficiency was defined as serum ferritin <13 microg/l and iron deficiency anemia as serum ferritin <13 microg/l and Hb <5th percentile in iron replete pregnant women.
There were no significant differences between variables in the four groups at inclusion. At 32 and 39 weeks of gestation, group 20 mg had significantly lower median serum ferritin (13 and 16 microg/l) than group 40 mg (17 and 21 microg/l), group 60 mg (18 and 23 microg/l), and group 80 mg (21 and 24 microg/l) (p < 0.0001). At 32 and 39 weeks of gestation, group 20 mg had a significantly higher prevalence of iron deficiency (50 and 29%) than group 40 mg (26 and 11%), group 60 mg (17 and 10%), and group 80 mg (13 and 9%) (p < 0.001). The prevalence of iron deficiency anemia at 39 weeks of gestation was significantly higher in group 20 mg (10%) than in group 40 mg (4.5%), group 60 mg (0%), and group 80 mg (1.5%) (p = 0.02). At 32 weeks of gestation, mean Hb in group 20 mg was lower than in group 80 mg (p = 0.06). There were no significant differences in iron status (ferritin, sTfR, and Hb) between group 40, 60, and 80 mg. Postpartum, group 20 mg had significantly lower median serum ferritin than group 40, 60, and 80 mg (p < 0.01). The prevalence of postpartum iron deficiency anemia was low and similar in the four groups. The frequency of gastrointestinal symptoms was not significantly different in the four iron supplement groups and thus not related to the iron dose.
In Danish women, a supplement of 40 mg ferrous iron/day from 18 weeks of gestation appears adequate to prevent iron deficiency in 90% of the women and iron deficiency anemia in at least 95% of the women during pregnancy and postpartum.
确定孕期预防缺铁及缺铁性贫血的最低铁剂量。
一项随机、双盲意向性治疗研究,纳入427名健康孕妇,分为四组,从妊娠18周起分别服用20毫克(n = 105)、40毫克(n = 108)、60毫克(n = 106)和80毫克(n = 108)的富马酸亚铁。在妊娠18周(纳入时)、32周、39周及产后8周测量铁状态标志物[血红蛋白(Hb)、血清铁蛋白和血清可溶性转铁蛋白受体(sTfR)]。记录铁补充剂的副作用。缺铁定义为血清铁蛋白<13微克/升,缺铁性贫血定义为血清铁蛋白<13微克/升且Hb低于铁储备充足孕妇的第5百分位数。
纳入时四组变量之间无显著差异。在妊娠32周和39周时,20毫克组的血清铁蛋白中位数(分别为13和16微克/升)显著低于40毫克组(17和21微克/升)、60毫克组(18和23微克/升)和80毫克组(21和24微克/升)(p < 0.0001)。在妊娠32周和39周时,20毫克组的缺铁患病率(分别为50%和29%)显著高于40毫克组(26%和11%)、60毫克组(17%和10%)和80毫克组(13%和9%)(p < 0.001)。妊娠39周时,20毫克组的缺铁性贫血患病率(10%)显著高于40毫克组(4.5%)、60毫克组(0%)和80毫克组(1.5%)(p = 0.02)。在妊娠32周时,20毫克组的平均Hb低于80毫克组(p = 0.06)。40毫克、60毫克和80毫克组之间的铁状态(铁蛋白、sTfR和Hb)无显著差异。产后,20毫克组的血清铁蛋白中位数显著低于40毫克、60毫克和80毫克组(p < 0.01)。四组产后缺铁性贫血的患病率均较低且相似。四种铁补充剂组的胃肠道症状频率无显著差异,因此与铁剂量无关。
在丹麦女性中,从妊娠18周起每天补充40毫克富马酸亚铁似乎足以预防90%的女性缺铁以及至少95%的女性在孕期和产后缺铁性贫血。